Swiss Xigen Completed €20M Series B Financing Round
Summary
Xigen SA, a Swiss biopharmaceutical company, with a focus on inflammation, announced the completion earlier this year of a €20m (CHF 20m) Series B financing round from existing investor Tilocor Life Science.Xigen develops innovative therapeutic peptides for a broad range of diseases with underserved medical needs and proven commercial value, with a focus on inflammation.The round allowed Xigen to complete a first-in-human Phase I study of its lead peptide drug candidate XG-102 administered intravenously.The company was founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland.Its CEO and co-founder, Dr. Christophe Bonny, is a renowned molecular biologist with over a decade’s research expertise on intracellular peptides and signalling.